These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32166894)

  • 1. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.
    Kalim M; Iqbal Khan MS; Zhan J
    Chem Biol Drug Des; 2020 Jun; 95(6):552-566. PubMed ID: 32166894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
    Gao T; Mao Z; Li W; Pei R
    J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
    Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
    Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
    ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures.
    Appleton KM; Elrod AK; Lassahn KA; Shuford S; Holmes LM; DesRochers TM
    Cancer Immunol Immunother; 2021 Mar; 70(3):843-856. PubMed ID: 33492447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
    Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
    Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway.
    Wang Z; Yuan L; Liao X; Guo X; Chen J
    J Med Chem; 2024 Apr; 67(8):6027-6043. PubMed ID: 38598179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
    Luan Y; Chai D; Peng J; Ma S; Wang M; Ma H; Li X; Fu S; Pan X; Wang X; Qin S; Xu T
    Int Immunopharmacol; 2016 Feb; 31():248-56. PubMed ID: 26773772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
    Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S
    Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442
    [No Abstract]   [Full Text] [Related]  

  • 19. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
    Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
    Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.